Dr. Miguel Albino, MD
What this data tells you about Dr. Albino
Dr. Miguel Albino is a medical oncology in Austin, TX, with 16 years in practice. Based on federal Medicare data, Dr. Albino performed 71,035 Medicare services across 2,079 unique beneficiaries.
Between the years covered by Open Payments, Dr. Albino received a total of $298,314 from 48 pharmaceutical and/or device companies across 575 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Albino is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) | 17,400 | $0 | $5 |
| Iron sucrose injection (Venofer) | 17,100 | $0 | $2 |
| Paclitaxel chemotherapy injection | 10,974 | $0 | $8 |
| Pembrolizumab injection (Keytruda) | 9,300 | $43 | $137 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 4,470 | $23 | $155 |
| Dexamethasone injection (steroid) | 2,280 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,430 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 970 | $0 | $24 |
| Injection of additional new drug or substance into vein | 587 | $13 | $108 |
| Injection, carboplatin, 50 mg | 514 | $2 | $300 |
| Epoetin alfa injection (Retacrit) for anemia | 510 | $6 | $28 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 500 | $3 | $373 |
| Injection, magnesium sulfate, per 500 mg | 454 | $1 | $6 |
| Complete blood count (CBC) with differential | 413 | $8 | $36 |
| Administration of chemotherapy into vein, 1 hour or less | 404 | $107 | $707 |
| Office visit, established patient (30-39 min) | 398 | $93 | $368 |
| Blood draw (venipuncture) | 383 | $8 | $20 |
| Comprehensive metabolic blood panel | 348 | $10 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 286 | $24 | $157 |
| Administration of additional new drug or substance into vein, 1 hour or less | 168 | $53 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 150 | $52 | $313 |
| Infusion, normal saline solution , 1000 cc | 147 | $2 | $19 |
| Injection, fluorouracil, 500 mg | 133 | $2 | $13 |
| Injection, diphenhydramine hcl, up to 50 mg | 130 | $1 | $7 |
| Administration of chemotherapy into vein, each additional hour | 129 | $23 | $161 |
| Injection, zoledronic acid, 1 mg | 120 | $6 | $431 |
| Drug injection, under skin or into muscle | 104 | $11 | $96 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 90 | $60 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 73 | $16 | $100 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 72 | $27 | $145 |
| Unclassified drugs | 72 | $1 | $8 |
| Infusion into a vein for hydration, each additional hour | 71 | $10 | $75 |
| Infusion into a vein for hydration, 31-60 minutes | 66 | $26 | $256 |
| Reticulated (young) platelet measurement | 61 | $35 | $143 |
| Ferritin level test (iron stores) | 57 | $13 | $60 |
| Immunoglobulin level test | 57 | $9 | $56 |
| Iron level test | 57 | $6 | $27 |
| Iron binding capacity test | 57 | $9 | $35 |
| Lactate dehydrogenase (enzyme) level | 47 | $6 | $31 |
| Measurement of immunoglobulin light chains | 38 | $17 | $60 |
| Irrigation of implanted venous access drug delivery device | 38 | $19 | $114 |
| Hospital follow-up visit, high complexity | 35 | $91 | $357 |
| Administration of additional new drug or substance into vein using push technique | 33 | $46 | $289 |
| Injection, lorazepam, 2 mg | 29 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 26 | $16 | $94 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $1 | $19 |
| Office visit, established patient, complex (40-54 min) | 21 | $138 | $496 |
| Drawing of blood for a medical problem | 20 | $74 | $264 |
| New patient office visit (45-59 min) | 20 | $125 | $565 |
| Office visit, established patient (20-29 min) | 19 | $58 | $250 |
| Red blood count, automated test | 18 | $4 | $23 |
| Protein measurement, serum | 17 | $11 | $99 |
| Immunologic analysis technique on serum | 16 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 16 | $22 | $160 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 15 | $1,205 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 15 | $90 | $657 |
| Flu vaccine administration | 14 | $31 | $58 |
| New patient office visit, complex (60-74 min) | 13 | $175 | $709 |
| Flu vaccine, quadrivalent | 12 | $76 | $171 |
| Initial hospital admission, moderate complexity | 12 | $99 | $470 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Albino is a mixed practice specialist, with above-average Medicare volume (top 14% in TX), and high industry engagement (speaking/promotional, top 6%), with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Albino experienced with anti-nausea injection (fosaprepitant)?
Does Dr. Albino receive payments from pharmaceutical companies?
How do Dr. Albino's costs compare to other medical oncologys in Austin?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology